摘要
目的 观察贝伐珠单抗联合安罗替尼治疗非小细胞肺癌的临床效果,并分析其对免疫状态的影响.方法 采用前瞻性随机对照研究,选取非小细胞肺癌患者作为研究对象,采用随机数字表法将患者分为观察组与对照组.对照组采用安罗替尼治疗,观察组实施安罗替尼联合贝伐珠单抗治疗.比较两组患者临床疗效、T淋巴亚群水平(CD4+、CD3+、CD8+、CD4+/CD8+)、血管内皮生长因子(VEGF)水平、卡氏功能(KPS)评分、肿瘤标志物水平[血清癌胚抗原(CEA)、糖类抗原 199(CA199)、CA125]、生存期及用药不良反应.结果 治疗前,两组患者各个指标比较,差异无统计学意义(P>0.05).治疗后,观察组患者疾病控制率(DCR)、客观缓解率(ORR)、CD4+、CD3+、CD4+/CD8+、KPS评分明显高于对照组(P<0.05);观察组CD8+、VEGF 水平、CEA、CA199、CA125 水平低于对照组(P<0.05).随访1 年,观察组患者中位生存期 6 个月,对照组患者中位生存期 5 个月,观察组患者总生存期明显长于对照组(lg rank=33.616,P<0.001).两组不良反应比较,差异无统计学意义(P>0.05).结论 贝伐珠单抗联合安罗替尼可改善非小细胞肺癌患者免疫功能及状态,延长生存期,降低肿瘤标志物与VEGF表达水平,具有良好的临床效果.
Abstract
Objective To observe the clinical effect of bevacizumab combined with anlotinib in the treatment of non-small cell lung cancer(NSCLC),and analyze its effect on immune status.Method A prospective randomized controlled study was conducted,selecting non-small cell lung cancer patients as the study subjects.The patients were divided into an observa-tion group and a control group using a random number table method.The control group was treated with anlotinib,and the observation group was treated with anlotinib combined with bevacizumab.The clinical efficacy,T lymphocyte subsets(CD4+,CD3+,CD8+,CD4+/CD8+),vascular endothelial growth factor(VEGF)level,KPS score,tumor marker level[serum carcinoem-bryonic antigen(CEA),carbohydrate antigen 199(CA199),CA125],survival time and adverse drug reactions were compared between the two groups.Results Before treatment,there was no statistical significant difference in various indicators between the two groups of patients(P>0.05).After treatment,the disease control rate(DCR),objective response rate(ORR),CD4+,CD3+,CD4+/CD8+,and KPS scores of the observation group were significantly higher than those of the control group(P<0.05).The levels of CD8+,VEGF,CEA,CA199,and CA125 in the observation group were lower than those in the control group(P<0.05).Following up for 1 year,the median survival time of the observation group patients was 6 months,while the median survival time of the control group patients was 5 months.The total survival time of the observation group patients was significantly longer than that of the control group(lg rank=33.616,P<0.001).There was no statistical significant difference in adverse reactions between the two groups(P>0.05).Conclusion The combination of bevacizumab and anlotinib can improve the immune function and functional status of patients with non-small cell lung cancer,prolong the survival period,reduce the expression of tumor markers and VEGF,and has a good clinical effect.
维普
万方数据